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Background
Folate Receptor Alpha (FRa) is an immunogenic protein
that is over-expressed in breast, endometrial and ovarian
cancer (OC). In fact, FRa expression in malignant cells is
20-fold higher compared to normal cells. We have begun
a phase 1 clinical trial with E39, an HLA-A2 restricted,
FRa peptide vaccine. The vaccine is administered in the
adjuvant setting to prevent recurrences in high-risk, endo-
metrial and OC patients (pts) rendered clinically disease-
free with standard-of-care therapy. Here, we summarize
toxicity and in vivo immunologic responses after enroll-
ment of three dose cohorts.
Methods
The trial is being performed as a 3x3, dose-escalation,
safety trial enrolling endometrial and OC pts. HLA-A2+
pts are enrolled into the vaccine group (VG) while
HLA-A2- pts are being followed prospectively as an
untreated control group (CG). Six monthly intradermal
inoculations (R1-R6) of either 100mcg, 500mcg, or
1000mcg of E39 + 250 mcg GMCSF immunoadjuvant are
administered during the primary vaccine series (PVS).
Immunologic responses are assessed by both local reaction
(LR) after each inoculation and delayed hypersensitivity
(DTH) reaction measured pre-vaccination (R0) and after
the PVS (R6). Recurrences are determined clinically. Data
are means compared with a paired, t-test.
Results
25 pts have enrolled; 13 in the VG and 12 in the CG.
There are no significant differences in age, grade, stage, or
nodal status between groups (all p>0.1). Overall, the vac-
cine was well tolerated (max local tox: 100% Grade (Gr) 1;
max systemic tox: 15% Gr 0, 70% Gr 1, 15% G r2). The LR
significantly increased from R1 to R2 (46.8mm+8.6 v
85.4mm+11.8, p<0.05), from R2 to R3 (85.4mm+11.8 v
120.5mm+11.4, p=0.01), and then plateaued R3-R6
(120.6mm+11.4 v 124.4mm+23.9, p=0.97). With five
patients completing R6, DTH increased from R0 to R6
(11.8mm+2.1 v 21.3mm+8.1, p=0.14). After a median
follow-up of 7 months, there has been 1 recurrence (7.7%)
in the vaccine group vs 3 recurrences (25%) in the CG
(p=0.32).
Conclusions
E39 is an immunogenic peptide derived from FRa. Results
from the first three dosing cohorts of this phase I trial
suggest the E39 vaccine is well tolerated and elicits a
strong in vivo immune response against Fra suggesting
that an expansion to a phase IIa trial to better evaluate
efficacy is warranted.
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